Tari M G, Mancino M, Monti G
Department of Internal Medicine, Center for the Study of Allergic Diseases, Arienzo, Caserta, Italy.
J Investig Allergol Clin Immunol. 1992 Mar-Apr;2(2):59-67.
The authors report the analysis of clinical and immunological parameters during local immunotherapy (LI) by inhalation of an extract in powder in patients with allergic asthma due to D. pteronyssinus (DP). The study was double-blind and lasted 24 months. Twenty-four patients were randomly assigned on a double-blind basis to receive by inhalation increasing doses of a micronized, freeze-dried DP extract in powder (14 patients, active therapy) or capsules of lactose (10 patients, placebo group). Results showed a statistically lower symptom score, a significant increase in bronchial tolerance to the allergen and significant levels of DP-specific IgG in actively treated patients compared to those treated with placebo.
作者报告了对因屋尘螨（DP）引起的过敏性哮喘患者进行吸入粉末状提取物局部免疫疗法（LI）期间的临床和免疫参数分析。该研究为双盲研究，持续了24个月。24名患者通过双盲方式随机分配，以吸入方式接受递增剂量的微粉化冻干DP粉末提取物（14名患者，积极治疗组）或乳糖胶囊（10名患者，安慰剂组）。结果显示，与接受安慰剂治疗的患者相比，积极治疗的患者症状评分在统计学上更低，对过敏原的支气管耐受性显著提高，且DP特异性IgG水平显著升高。
